Nasar Aslam

Nasar Aslam


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
NANasar Aslam
Nasar Aslam
SLSheng Wei Lo
Sheng Wei Lo
RSRafid Sikafi
Rafid Sikafi
TBTom Barnes
Tom Barnes
Jonathan SegalJonathan Segal
Jonathan Segal
JLJimmy K Limdi
Jimmy K Limdi
Ulcerative colitis (UC) is a chronic relapsing and remitting gastrointestinal disorder of uncertain aetiology. The last two decades have seen an expansion in the therapeutic arsenal used to treat UC. This has resulted in improved clinical remission and response rates. Nonetheless, staples in our current medical management originate from trials conducted in the early 20th century. In this review article, we aim to outline the key milestones in the history of the medical management of UC in addition to highlighting promising therapeutic developments for the future.

8 April 2022 in Drugs in Context
Verified
Journal Article
Open access
ELEleanor Liu
Eleanor Liu
NANasar Aslam
Nasar Aslam
GNGaurav Nigam
Gaurav Nigam
JLJimmy K Limdi
Jimmy K Limdi
Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn’s disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the National Institute for Health and Care Excellence (NICE) for use in moderately-to-severely active UC after intolerance, inadequate response, or loss of response to conventional treatment or biologic therapy. The pivotal OCTAVE studies demonstrated the efficacy and safety of tofacitinib for the induction and maintenance of remission in UC. A growing body of evidence from real-world data supports the positive clinical and endoscopic benefits observed with tofacitinib treatment in the OCTAVE trials. This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. We explore evolving treatment paradigms, including the use of tofacitinib in the COVID-19 era, pregnancy and extraintestinal manifestations, as well as the emerging concept of combining tofacitinib with biological therapy. We will also present a brief overview of the next generation of JAK inhibitors in the pipeline.

2 February 2023 in Frontline Gastroenterology
Verified
Journal Article
Open access
PDF file
NANasar Aslam
Nasar Aslam
ATAndrea Telese
Andrea Telese
VSVinay Sehgal
Vinay Sehgal
RSRami Sweis
Rami Sweis
LLLaurence B Lovat
Laurence B Lovat
RHRehan Haidry
Rehan Haidry
The prevalence of the gastro-oesophageal reflux disease (GORD) in the western world is increasing. Uncontrolled GORD can lead to harmful long-term sequela such as oesophagitis, stricture formation, Barrett’s oesophagus and oesophageal adenocarcinoma. Moreover, GORD has been shown to negatively impact quality of life. The current treatment paradigm for GORD consists of lifestyle modification, pharmacological control of gastric acid secretion or antireflux surgery. In recent years, several minimally invasive antireflux endoscopic therapies (ARET) have been developed which may play a role in bridging the unmet therapeutic gap between the medical and surgical treatment options. To ensure optimal patient outcomes following ARET, considered patient selection is crucial, which requires a mechanistic understanding of individual ARET options. Here, we will discuss the differences between ARETs along with an overview of the current evidence base. We also outline future research priorities that will help refine the future role of ARET.

13 September 2023 in Life
Verified
Journal Article
Open access
PDF file
BNBenjamin Charles Norton
Benjamin Charles Norton
ATAndrea Telese
Andrea Telese
APApostolis Papaefthymiou
Apostolis Papaefthymiou
NANasar Aslam
Nasar Aslam
JMJanine Makaronidis
Janine Makaronidis
RHRehan Jamil Haidry
Rehan Jamil Haidry
We are currently in a worldwide obesity pandemic, which is one of the most significant health problems of the 21st century. As the prevalence of obesity continues to rise, new and innovate treatments are becoming available. Metabolic and bariatric endoscopic procedures are exciting new areas of gastroenterology that have been developed as a direct response to the obesity crisis. These novel interventions offer a potentially reversible, less invasive, safer, and more cost-effective method of tackling obesity compared to traditional bariatric surgery. Minimally invasive endoscopic treatments are not entirely novel, but as technology has rapidly improved, many of the procedures have been proven to be extremely effective for weight loss and metabolic health, based on high-quality clinical trial data. This mini-review examines the existing evidence for the most prominent metabolic and bariatric procedures, followed by a discussion on the future trajectory of this emerging subspecialty.

23 April 2025 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
APApostolis Papaefthymiou
Apostolis Papaefthymiou
NANasar Aslam
Nasar Aslam
BNBenjamin Charles Norton
Benjamin Charles Norton
ATAndrea Telese
Andrea Telese
CMCharles Murray
Charles Murray
RHRehan Jamil Haidry
Rehan Jamil Haidry
Background: The increasing availability of gastrointestinal (GI) interventions has raised the need to treat luminal defects. Endoscopic suturing (ES) is a minimally invasive technique that is used for a wide range of indications. This retrospective cohort study aimed to evaluate the performance of ES in treating upper GI defects. Materials and Methods: Data from a tertiary centre were collected for patients undergoing ES to treat upper GI defects. The primary outcome was long-term outcomes, defined as the successful sutures deployment. Secondary outcomes included technical success, immediate clinical success (confirmation of closure at the time of the procedure), recurrence, and complications. Descriptive statistics and x2 test were used to calculate the rates of the outcomes and assess any link between independent variables and results. Results: Forty-two procedures were performed on 25 patients between 2018 and 2023. The mean age was 55 (±16.2) years, and 56% were female. The long-term clinical success rate was 69.6% (16/23), the technical success rate was 88.1% (37/42), and the immediate clinical success rate was 91.9% (34/37), with only two (4.8%) adverse events. The overall recurrence rate was 61.8% (21/34). Technical success was higher in the esophagus (92.3%), and stomach (100%) (p = 0.002), and immediate clinical success was more likely in patients with leaks (88.9%) or fistula (95.2%) compared to perforation (50%; p = 0.005). Conclusions: ES demonstrated high rates of technical and immediate clinical success for defect closure in the upper GI tract, with low rates of complications. The benefit is most prominently seen among patients with leaks and fistulas in the stomach and esophagus.

29 July 2026 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
CGChampika Gamakaranage
Champika Gamakaranage
JBJames Britton
James Britton
ERElizabeth Ratcliffe
Elizabeth Ratcliffe
NPNeeraj Prasad
Neeraj Prasad
RKRichard Keld
Richard Keld
DGDEBO group
DEBO group
Background: Dedicated service for Barrett's oesophagus (BO) surveillance may be more effective than conventional service, according to some single centre studies. Objective: To determine whether the surveillance of BO through a dedicated service can improve key performance indicators (KPIs), and dysplasia detection rate (DDR) compared with conventional service in a multi centre study. Methods: A retrospective cohort study was conducted across 6 NHS‐hospitals, capturing BO surveillance data over 8 years. Factors associated with DDR were assessed by logistic regression. Results: There were 1037 dedicated and 976 conventional surveillance procedures ( N = 2013), male: female ratio = 2.2:1; mean age = 64.4 (SD ± 12.2) years; mean maximum length of BO = 4.1 cm (range: 0–18 cm). All the KPIs and DDR were significantly higher in the dedicated service (DDR = 6.9%) than in the conventional service (DDR = 2.8%), p < 0.001. The use of narrow band imaging (NBI) and acetic acid chromoendoscopy (AAC) and sedation were high, and the complication rate was significantly lower in the dedicated service. The lesion recognition was significantly associated with DDR (OR = 6.9). Surprisingly, Seattle biopsy protocol adherence showed no correlation with DDR (OR = 0.47). Conclusion: The dedicated service provides higher quality endoscopy, and a higher yield of early neoplasia. It uses more sedation, advanced imaging, and detects more lesions than conventional services. Thus, the dedicated surveillance could potentially replace time and cost consuming Seattle biopsies with targeted biopsies of visible lesions. In future, this may become easier with the use of artificial intelligence for lesion detection (CADe).